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Summary The aim of the study was to investigate the
safety of adenosine 5′-triphosphate (ATP) administration at
home in pre-terminal cancer patients. Included were
patients with cancer for whom medical treatment options
were restricted to supportive care, who had a life
expectancy of less than 6 months, a World Health
Organization performance status 1 or 2, and suffered from
at least one of the following complaints: fatigue, anorexia
or weight loss >5% over the previous 6 months. Side
effects were registered systematically on a standard form
according to the National Cancer Institute (NCI) Common
Toxicity Criteria. Fifty-one patients received a total of 266
intravenous ATP infusions. Of these, 11 infusions (4%)
were given at the lowest dose of 20 μgk g
−1 min
−1,8 5
infusions (32%) at 25–40 μgk g
−1 min
−1, and 170 (64%) at
the highest dose of 45–50 μgk g
−1 min
−1 ATP. The majority
of ATP infusions (63%) were without side effects. Dyspnea
was the most common side effect (14% of infusions),
followed by chest discomfort (12%) and the urge to take a
deep breath (11%). No symptoms of cardiac ischemia
occurred in any of the infusions. All side effects were
transient and resolved within minutes after lowering the ATP
infusion rate. Side effects were most frequent in the presence
of cardiac disorders. We conclude that ATP at a maximum
dose of 50 μgk g
−1 min
−1 can be safely administered in the




In recent years favorable effects of adenosine 5′-triphosphate
(ATP) on nutritional and functional status and survival in
cancer patients were reported [1–5]. However, ATP [6–10]
and its breakdown product adenosine [11–18], given either
as a continuous intravenous infusion or by intravenous
bolus administration, were also reported to have side ef-
fects, which might hamper administration especially in an
outpatient setting.
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intravenous infusions over several hours, in doses varying
from 25 to 100 μgk g
−1 min
−1. In a Phase I study [4], 14
patients with advanced cancer received 96-h infusions of
ATP once per month for a total of at least three infusions, as
tolerated by the patient. In the first three patients, ATP was
given at a dose of 50 μgk g
−1 min
−1. If well tolerated,
subsequent dose escalations were planned in groups of
three patients in increments of 25 μgk g
−1 min
−1 until the
maximally tolerated dose (MTD) was reached. Patients who
completed therapy without serious toxicity and later
progressed were eligible for retreatment at a higher dose
of ATP. Fourteen patients received a total of 43 ATP
infusions: 11 patients received 29 infusions at a dose of
50 μgk g
−1 min
−1, six patients received 11 ATP infusions at
a dose of 75 μgk g
−1 min
−1, and three patients who had
tolerated 50 μgk g
−1 min
−1 very well were reconsented and
received one cycle each at a dose of 100 μgk g
−1 min
−1.
In total, 179 adverse events were reported, whether or
not these could be ascribed to ATP. The majority of side
effects (dyspnea, chest pain, hypotension, gastrointestinal
side effects, dizziness, headache, fever and local injection
site reaction) were minor (104 adverse events grade 1
(58%) and 54 adverse events grade 2 (30%) based on the
US National Cancer Institute Toxicology Criteria. Dose-
limiting toxicities of ATP were reported in seven patients,
i.e. asymptomatic electrocardiographic evidence of cardiac
ischemia (n=2), grade 3 cardiac toxicity (angina without
evidence of infarction), and grade 4 pulmonary toxicity
(dyspnea at rest), usually occurring as a characteristic
cardiopulmonary syndrome including an initial feeling of
chest ‘tightness’ and a sensation of ‘needing to take a deep
breath’ (n=5). Dose-limiting cardiopulmonary toxicity
appeared in all three 100 μgk g
−1 min
−1 ATP infusions, in
four (36%) 75 μgk g
−1 min




In a subsequent uncontrolled phase II study [5], 15
previously untreated patients with stage IIIB/IV non-small-
cell lung cancer (NSCLC) received infusions of ATP at
doses of 50 (first course) and 65 μgk g
−1 min
−1 (subsequent
courses) for 96 h every 4 weeks. Reported side effects
were, in decreasing frequency, chest pain, dyspnea, cough-
ing, anxiety, injection site pain, chest tightness, headache,
insomnia, and hot flushes. According to the authors, six
patients reported severe adverse events, of which CTC 4
dyspnea occurred in two patients; this led to the cessation
of treatment in five patients [5].
In the first randomized clinical trial with ATP [1], 28
patients with stage IIIB/IV NSCLC received a total of 176
intravenous ATP courses, at doses of maximally 75 μgk g
−1
min
−1 (tailored to the maximum tolerance of each patient) for
30 h every 2–4 weeks. Twenty-nine percent of the infusions
were given at rates of 25–40 μgk g
−1 min
−1, 27% at 45–
60 μgk g
−1 min
−1 and 44% at 65–75 μgk g
−1 min
−1 [19].
The most frequent side effects were chest discomfort (15%)
and the urge to take a deep breath (10%), both of which
resolved within minutes after lowering the ATP dose.
Electrocardiography (ECG) was performed in patients with
chest pain/discomfort during the ATP infusions, but no ECG
changes suggestive of myocardial ischemia were detected
[19]. In all of the above studies, ATP was administered on an
inpatient basis under medical supervision.
Based on the previously reported favorable effects of
ATP on quality of life, nutritional status and survival [1, 3],
we initiated a new randomized clinical trial to investigate
whether these effects of ATP could be confirmed in patients
with different types of cancer in the pre-terminal stage of
disease (life expectancy 1–6 months). In view of the short
life expectancy of these patients, and based on the favorable
safety profile of ATP, we decided to administer ATP in the
home setting.
The aim of the present study was to investigate the safety
of ATP administration at home in pre-terminal cancer
patients. We hypothesized that side effects of ATP infusions
would occur mainly during the first ATP infusion, es-
pecially during assessment of the MTD of ATP. We also
hypothesized that the presence of cardiac disorders and/or
lung cancer would lead to a lower MTD, and a higher
frequency of side effects.
Patients and methods
Study population and design
Patients were recruited through the Departments of Medical
Oncology and Pulmonology of five hospitals in different
regions in The Netherlands (Maastricht, Eindhoven, Utrecht
and Heerlen) and through general practitioners in the region
of Maastricht. Eligible were patients with cytologically or
histologically confirmed cancer, for whom medical treat-
ment options were restricted to supportive care, who had a
life expectancy <6 months, had a World Health Organiza-
tion (WHO) performance status 1 or 2, and who at the time
of inclusion suffered from at least one of the following
complaints: fatigue, anorexia, or weight loss >5% in the
previous 6 months. Exclusion criteria were: symptomatic
angina pectoris, symptomatic heart failure, atrio-ventricular
block (checked by standard ECG in all patients before
inclusion), life expectancy of less than 4 weeks, concurrent
palliative chemotherapy at the time of inclusion, cognitive
dysfunction, and the presence of other diseases hamper-
ing adequate follow up. The eligibility of patients was
evaluated by a medical oncologist or pulmonologist. After
baseline measurements, patients were randomly allocated to
572 Invest New Drugs (2007) 25:571–579ATP or control treatment. The present report on the safety
of ATP administration is restricted to patients randomized to
ATP treatment. The study was approved by the Ethical
Committee of University Hospital Maastricht and Maas-
tricht University, and all patients signed written informed
consent prior to the study. Details of the trial design have
been published elsewhere [20].
Intervention
Adenosine 5′-triphosphate (ATP-Na2) of >98% purity was
purchased from Pharma Waldhof GmbH and co. KG
(Düsseldorf, Germany). For each infusion, 2.5 g of ATP
were dissolved in 500 ml NaCl 0.9%, sterilized by
ultrafiltration (Minisart 0.22 μM), and supplied in sterile
containers. Patients received weekly intravenous ATP
infusions of 8–12 h, over a period of 8 weeks. All ATP
infusions were started at a dose of 20 μgk g
−1 min
−1 and
then increased in steps of 10 μgk g
−1 min
−1 every 10 min,
until a maximum dose of 50 μgk g
−1 min
−1, or the MTD, if
this was lower, had been reached. Thereafter, ATP was
infused at a continuous rate. If any side effects occurred, the
dose was reduced until side effects disappeared. Blood
pressure and pulse were registered before starting the
infusion, at 30 min after determining the MTD, and just
before the infusion was stopped.
Since initiation of ATP infusions under medical super-
vision in a clinical setting would facilitate the treatment of
possible side effects, the first two ATP infusions were given
at the day care center of the participating hospitals. Based
on evaluation of safety data in the first 22 patients, in view
of the mild character of the noted side effects during the
first two infusions in these patients, the Ethical Committee
granted permission to administer only the first ATP infusion
at the day care center and all subsequent infusions at home.
The description below applies to the procedures in case of
only one hospital infusion.
At the end of the first infusion, the safety and
tolerated dose of ATP was evaluated for each individual
patient. Subsequent infusions were given at the patients’
home by an experienced and trained nurse of a spe-
cialized infusion team, usually embedded in the regional
Community Care Organization. The MTD as determined
during the first infusion at the day care center was also
the maximum dose for this patient for the next infusions
at home. The same rule was applied for subsequent home
infusions, so that the infusion rate in any subsequent
ATP infusion course was never higher than the MTD
during the previous ATP infusion. Patients and their
partners were instructed extensively regarding the infu-
sion procedures; also, they were instructed to immediate-
ly call the involved infusion team in case of any side
effects.
Documentation of side effects and adverse events
Side effects of ATP infusions
Side effects of all ATP infusions, adjustments of dosage
schedules, and any other events occurring during the infusions
were registered by the infusion nurse, either a. during the
infusions, or b. on completion of each infusion. In addition, the
researcher called all patients after each infusion to ask whether
any side effects had occurred. Side effects were scored using
the NCI Common Toxicity Criteria [21] on a four-point scale,
according to seriousness. In this system, dyspnea is graded
as follows: 0, no change; 1, not defined; 2, dyspnea on sig-
nificant exertion; 3, dyspnea at normal activity; 4, dyspnea
at rest. Since most terminal cancer patients are at rest, dyspnea
would in these cases automatically be classified as CTC grade
4, which would misrepresent the actual severity of the
symptoms and disregard the intention of the NCI Common
Toxicity Criteria (i.e. CTC grade 4=life-threatening). For this
reason, we decided to apply the general toxicity grading of the
CTC also for dyspnea, i.e. 1, mild; 2, moderate; 3, severe; and
4, life-threatening.
Based on Agteresch et al. [19], we pre-defined 13 side
effects: chest discomfort, urge to take a deep breath, nausea,
flushing, light-headedness, dyspnea, headache, sweating,
mood alteration-anxiety, palpitations, epistaxis, symptoms
of cardiac ischemia, injection side reaction or other (to be
specified). In case of persistent or severe chest pain, suspect
for potential cardiac ischemia, an ECG was made in order
to exclude this.
Statistical analysis
Data were entered in a database using Microsoft Access
2000 and checked for errors by means of double data entry
by two independent persons. Data were analyzed using
SPSS 13.0 for Windows. Changes in blood pressure and
heart rate over time were tested for statistical significance
by Student’s paired t test. To test our hypothesis that side
effects would especially occur during the first infusion, we
calculated the average number of side effects per infusion
over all infusions. To investigate whether the MTD and
frequency of side effects were dependent on the presence of
cardiac disorders and/or lung cancer, linear regression
models were fitted. As dependent variables, we used mean
MTD per patient over all courses, and frequency of side
effects per infusion. As independent variables, we included
dummy variables for the presence of cardiac disorders (yes/
no), and lung cancer (yes/no).To investigate the relation
between the seriousness of side effects (CTC grades 2–4 vs.
CTC grade 1) and the presence of cardiac disorders and/or
lung cancer, Fisher’s exact test was used. P values of less
than 0.05 indicated significance.
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Study population
Fifty-one patients with different types of pre-terminal cancer
were included in the present study. Baseline characteristics of
the patients are listed in Table 1. Mean age was 68.1 years
(range: 45–87 years) and the majority of patients were male
(69%). The most frequent diagnosis was lung cancer (41%),
followed by colon cancer (16%). The majority of patients
(65%) had WHO performance status 1, and 35% WHO status
2. Twelve patients (24%) suffered from cardiac disorders.
Out of 51 patients, six patients died during the interven-
tion period because of disease progression (Fig. 1). Three
patients did not start because of rapid deterioration of their
condition and 18 patients stopped with the ATP infusions.
Reasons to stop were deterioration in medical condition
(n=11), fear of side effects (n=4), or being unsatisfied with
the effect of ATP (n=3).
Over the study period of 8 weeks, a total of 266 ATP
infusions were administered in 48 patients. Fifteen patients
(31%) received one to three ATP courses, nine patients (19%)
received four to seven courses, and 24 patients (50%)
completed all eight ATP infusions. Eleven infusions (4%) of
266 infusions were given at the lowest dose of 20 μgk g
−1
min
−1, 85 infusions (32%) at a dose of 25–40 μgk g
−1 min
−1,
and 170 (64%) at the highest dose of 45–50 μgk g
−1 min
−1.
Heart rate and blood pressure
Heart rate decreased from 86±1 (mean±SEM) at baseline to
83±1 at 30 min after reaching the MTD (p<0.001), and
thereafter remained constant at 83±1 beats/min, as measured
at 8–10 h of ATP administration (comparison with baseline:
p<0.001). Systolic blood pressure decreased from 126±1 at
baseline to 124±2 at 30 min (p<0.001), but then increased to
1 3 3 ± 2m mH ga t8 –10 h of ATP infusion (comparison with
baseline: p<0.001). Diastolic blood pressure also initially
d e c r e a s e df r o m7 5 ±1m m H gt o7 2 ±1m m H g( p<0.001), but
then increased to 77±1 mm Hg at 8–10 h of ATP infusion
(comparison with baseline: p=0.02).
Side effects
Ten patients out of 48 had no side effects during any of
the infusions. Out of 266 infusions, 167 infusions (63%)
were without any side effects. In 48 infusions (18%) 1
side effect occurred, in 29 infusions (11%) 2 side effects,
and in 22 infusions (8%) >2 side effects. In total, 192
side effects were reported (Fig. 2): 138 side effects (72%)
were reported to the nurse, of which 96 during the infusions
and 42 afterwards; and 54 (28%) to the researcher when
specifically asked for. The average number of side effects
per infusion was 0.72 (i.e. 192 side effects in 266
infusions).
At the day care center, 63 side effects were reported in
95 infusions (0.66 side effect per infusion). Of these 63 side
effects, 56 (89%) were reported to the nurse, of which 55
during the infusions and 1 afterwards; and 7 (11%) to the
researcher when specifically asked for. At home, 129 side
effects were reported in 171 infusions (0.75 side effect per
infusion); of these, 82 (64%) were reported to the nurse, of
which 41 during the infusions and 41 afterwards; and 47
(36%) to the researcher when specifically asked for. All
side effects were transient and resolved within minutes after
lowering the ATP infusion rate.
In a total of 99 infusions, one or more side effects were
reported by patients. In the 51 infusions with one or more
side effects reported during ATP administration, the
infusion was stopped in 13 infusions (25%), lowered in
30 infusions (59%) and not changed in 8 infusions (16%).
Of the latter eight infusions, the side effects had already
disappeared before lowering the infusion rate in four
infusions, whereas in three infusions the side effects had
already been present before the start of the ATP infusions;
in one infusion, extravasation occurred, and the ATP
infusion was temporarily interrupted. In 48 out of the total
of 99 infusions with one or more side effects, the side
effects were reported by patients to the nurse or researcher
only after completion of the infusion, and the infusion rate
was therefore not adapted.
The frequency of specific side effects observed during
the ATP infusions is shown in Table 2. Dyspnea was the
most frequent side effect, appearing in 36 out of 266
infusions (14%), followed by chest discomfort (12%) and
Table 1 Baseline characteristics of ATP-treated patients (n=51)
Number Percent (%)







13 3 6 5




Gastro-intestinal other 6 12
Prostate 5 10
Other 11 21
Presence of cardiac disorders 12 24
aMean (range)
bWHO 1: restricted in physically strenuous activity but ambulatory
and able to do light work; WHO 2: ambulatory (not more than 50% in
bed) and capable of self-care but unable to carry out any work
574 Invest New Drugs (2007) 25:571–579the urge to take a deep breath (11%). No symptoms of
cardiac ischemia occurred in any of the infusions.
From the 192 side effects, one side effect (lightheaded-
ness) occurred at the day care center and was scored by the
nurse as CTC 4 because of prolonged stay (one night) at the
hospital after the first infusion; there were no abnormalities
on ECG. Four side effects were scored as CTC 3 (in all cases
chest discomfort), and 22 side effects as CTC 2. Two CTC 3
side effects occurred at the day care center in two patients,
with no abnormalities on ECG. Of these, one patient decided
to stop with the ATP infusions. The other patient wanted to
continue; for safety reasons, all subsequent infusions in this
patient were given at the day care center. The remaining two
CTC 3 side effects occurred at home: one in a patient during
the normal procedure of stepwise increasing the infusion rate
by the nurse according toprotocol, inthe other patientduring
constantATPinfusion after the nurse had left; in the latter











51 patients  
total 6 died  24 patients 
completed 8 
infusions 
12 patients continued 
ATP infusions after 
completion of the 8 
regular infusions 








2 patients stopped 
3 patients stopped 
6 patients stopped 
3 patients stopped 
1 patient stopped 
2 patients stopped 
1 patient stopped 
1 patient died 
3 patients died 
2 patients died 
21 did not 
complete 8 
infusions 
Fig. 1 Flow diagram of the
study
Invest New Drugs (2007) 25:571–579 575informal caregiver and immediately arrived. In both
cases, the infusions were stopped immediately for that
very day. The first patient decided to continue the ATP
infusions; in this patient, all four subsequent infusions
until the end of the study were given at the day care
center at the highest ATP dose (50 μgk g
−1 min
−1), and
no further side effects occurred. The second patient decided
to stop the ATP infusions.
192 side effects in 
266 infusions 
Day care center 
63 side effects  
in 95 infusions 




129 side effects  
in 171 infusions 
8 side effects  
reported after 
the infusions 
41 side effects  
reported during 
the infusions 
88 side effects  
reported after
the infusions 
41 to the nurse 
47 to the researcher 
1 to the nurse 
7 to the researcher 
28 side effects 
reported during 
MTD assessment 
27 side effects 
reported after  
MTD assessment 
19 side effects 
reported after 
MTD assessment 
22 side effects 
reported during 
MTD assessment 
Fig. 2 Reported side effects of
ATP according to location (day
care centre vs. home), time of
reporting side effects (during vs.
after the infusion), and person to
whom the side effects were
reported (nurse vs. researcher)
Table 2 Side effects during a
total of 266 intravenous ATP
cycles in 51 patients;
CTC-grading
In some courses more than one
side effect was observed
aThe side effects classified as
‘Other’ were cold shivering,
feelings of coldness, pain in
infusion arm, dry eyes, sleepi-
ness, burning sensation of the
throat, vomiting, diarrhea, pain
neck, general discomfort and
unspecified
No side effects Side effects according to CTC grade Total side effects




Cardiac ischemia 266 0 0 0 0 0 0 0
Chest discomfort 234 26 1 4 0 1 32 12
Dyspnea 230 35 1 0 0 0 36 14
Epistaxis 266 0 0 0 0 0 0 0
Flushing 258 8 0 0 0 0 8 3
Headache 252 11 2 0 0 1 14 5
Injection side reaction 261 5 0 0 0 0 5 2
Lightheadedness 254 9 2 0 1 0 12 5
Mood alteration-anxiety 262 4 0 0 0 0 4 2
Nausea 251 14 1 0 0 0 15 6
Other
a 235 28 2 0 0 1 31 12
Palpitations 265 1 0 0 0 0 1 0
Sweating 260 2 3 0 0 1 6 2
Urge to take a deep breath 238 18 10 0 0 0 28 11
Total 161 22 4 1 4 192
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patients:
1. To the nurse during the infusions, by seven patients in
seven infusions:
– Urge to breathe deeply, headache, sweating and
cold shivering in one patient at the day care center
(the same patient with the CTC 3 chest discomfort
and CTC 4 lightheadedness)
– Sweating in one patient at the day care center at the
end of the infusion, due to flushing the infusion
line (violation of the administration protocol)
– Pain in the infusion arm (one patient) and dyspnea
(one patient), both at the day care center
– Urge to breathe deeply, headache and sweating in
one patient at home, during the period of stepwise
increasing the infusion rate by the nurse
– Chest discomfort (once) and lightheadedness (twice)
at home in two patients, who called the home nurse
Out of these seven patients with CTC 2 side effects,
two patients decided to stop the ATP infusions for the
rest of the study.
2. To the nurse after completion of the infusion, by three
patients (four infusions)
3. To the researcher when specifically asked for, by one
patient (five infusions)
These nine CTC 2 side effects (eight times urge to
breathe deeply, once nausea), were probably not
sufficiently serious to call the home nurse. All of these
patients continued the ATP infusions.
Timing of side effects
Side effects were not only present during the first infusion but
also during subsequent infusions, even though the number of
side effects per infusion appeared to be lower during the last
three infusions (Fig. 3). At the day care center, of the 55 side
effects reported during the infusions, 28 (51%) were reported
during MTD assessment and 27 side effects (49%) after
MTD assessment had been completed (Fig. 2). At home, 41
side effects were reported during the infusion, 22 side effects
(54%) during MTD assessment, and 19 side effects (46%)
after MTD assessment had been completed. In the latter 19
cases of side effects, the nurse (and once the general
practitioner) was called by the patient and visited the patient
to lower or stop the infusion rate.
Effect of cardiac or lung disorders on MTD
and frequency of side effects
Mean MTD was 48±2 (mean±SEM) μgk g
−1 min
−1 in
patients without cardiac disorders and/or lung cancer
(Table 3). In the presence of cardiac disorders mean MTD
was 8 μgk g
−1 min
−1 lower (p<0.001) and 4 μgk g
−1 min
−1
lower in the presence of lung cancer (p=0.02). The mean
number of side effects per infusion was 0.71±0.28 in
patients without cardiac disorders and/or lung cancer. In the
presence of cardiac disorders, the number of side effects was
significantly higher: 2.25±0.49 (p=0.02). The presence of
lung cancer had no significant impact on the frequency of
side effects (0.66±0.34). Neither the presence of cardiac
disorders, nor the presence of lung cancer had a significant
impact on the frequency of specific complaints (chest
discomfort, urge to breathe deeply, nausea, lightheadedness,
or dyspnea). However, in the presence of cardiac disorders,
the number of other side effects was significantly higher (p=
0.006). The proportion of CTC grade 2–4 side effects in the
presence of cardiac disorders and/or lung cancer (21 CTC
grades 2–4 out of 133 side effects, i.e. 16%) was similar to
patients without such disorders (seven CTC grades 2–4o u t
of 59 side effects, i.e. 12%).
Table 3 The independent effect of the presence of cardiac disorders







MTD 48±2 40±3*** 44±2*
All side effects 0.71±0.28 2.25±0.49* 0.66±0.34
Chest discomfort 0.14±0.05 0.32±0.09 0.12±0.06
Urge to breathe deeply 0.08±0.05 0.25±0.08 0.09±0.05
Nausea 0.06±0.04 0.18±0.07 0.03±0.05
Lightheadedness 0.06±0.04 0.14±0.08 0.06±0.05
Dyspnea 0.12±0.05 0.35±0.09 0.17±0.06
Other 0.09±0.06 0.42±0.11** 0.05±0.07











































Fig. 3 Average number of side effects per ATP infusion in subsequent
infusions
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Of the 24 patients who completed all eight ATP infusions,
12 decided to continue ATP administration (nine patients
with lung cancer, one with prostate cancer, one with a
malignant melanoma, one with liver cancer). Until the
censoring date, these patients had received a total of 116
ATP infusions after completion of the regular 8-week study
period (range 1–34 additional infusions). Of these 116
infusions, 11 infusions (10%) reached a dose of ≤20 μg
kg
−1 min
−1, 72 infusions (62%) were given at a dose of 25–
40 μgk g
−1 min
−1, and 33 (28%) reached a dose of 45–
50 μgk g
−1 min
−1 ATP. A total of 38 side effects were
reported over 116 infusions (0.33 side effects per infusion),
a number significantly lower (p<0.001) than in the first
8 infusions in the same 12 patients.
Discussion
The aim of this study was to investigate whether ATP can
be safely administered to patients with pre-terminal cancer
in the home setting. A total of 266 infusions were adminis-
tered for 8–12 h. Although statistically significant changes
in blood pressure and heart rate were observed, these were
minor and clinically irrelevant, corroborating earlier results
[19]. In total, 192 side effects were reported during the
266 ATP infusions, i.e. an average of 0.72 side effects
per infusion. Most side effects were mild and transient,
presumably due to the short plasma half-life of ATP and
adenosine (0.6–1.5 s) [22].
We saw more side effects than in a previous study in 28
lung cancer patients by Agteresch et al. [19]. These authors
observed 91 side effects during a total of 176 ATP cycles of
30 h (0.52 side effects per infusion), even though these
infusions were administered for a longer period of time
(30 h vs 8–10 h in our study). One possible explanation of
this discrepancy may be the different procedures of data
collection in these two studies. For safety reasons, the
safety procedure adopted in the present study was that the
researcher contacted the patients after each home infusion
to ask for side effects, specifically naming a number of the
most common potential side effects (based on side effects
listed by Agteresch et al. [19]. Our results clearly
demonstrate that this procedure lead to a higher frequency
of reported side effects in our study: out of a total number
of 192 side effects, 54 side effects (28%) were reported
only afterwards to the researcher when specifically asked
for. If these side effects (i.e. side effects which had not
spontaneously been reported to the nurse during or after the
infusion) are excluded, the frequency of the remaining side
effects per infusion in the present study (138/266; 0.52) is
remarkably similar to the report by Agteresch et al. [19]
(91/176; 0.52), in which trained research nurses in a
dedicated clinical research unit registered the side effects.
InbothourstudyandthestudiesbyHaskelletal.[4, 5]a n d
Agteresch et al. [19], chest discomfort/pain, dyspnea and the
urge to take a deep breath were frequent side effects.
Results showed that in 43 out of 51 infusions (84%) with
side effects reported during ATP administration, the
infusion rate was lowered or stopped according to protocol.
Reasons for not lowering the infusion rate in eight infusions
were the fact that in four infusions complaints disappeared
automatically; in three infusions the reported complaints
were already present before the start of the infusion; and in
one infusion extravasation occurred with a temporary
interruption of the ATP infusion.
In 48 infusions with side effects, side effects had only been
reported after completion of the concerned ATP infusion and
the infusion rate was therefore not adapted. One potential
explanation for this finding may be that patients were eager to
receive ATP at the highest possible dose, as some patients
expressed their worry that the potential effectiveness of
ATP could fade in case of lowering the dose (similar to
chemotherapy), despite our explicit explanation to patients
prior to the study that there is currently no evidence that the
efficacy of ATP would be better at higher ATP doses. Another
possible explanation is that patients in our study population
were used to experiencing far more serious complaints caused
by progression of the disease and/or previous antitumor
treatment.
One CTC 4 side effect, four CTC 3 side effects, and 22
CTC score 2 were observed. The CTC 4 side effect (see
“Results”), and two CTC 3 side effects (chest discomfort)
occurred at the day care center, with no abnormalities on
ECG. The other two CTC 3 side effects occurred at home,
one with the nurse still being present; and in the other case,
the nurse immediately arrived.
Side effects were not limited to the period of MTD
assessment, nor were they limited to the first ATP infusion.
The implication of this finding is that alertness with regard
to potential side effects of ATP administration is necessary
during all subsequent ATP infusions, and not just during the
first infusion or MTD assessment.
The lower MTD found in the presence of cardiac
disorders or lung cancer indicates that patients with these
disorders tolerate lower doses of ATP without side effects
than patients without these disorders. Moreover, even at the
lower MTD, side effects tend to be more frequent in the
presence of cardiac disorders. Because all patients with
presence of COPD also had cardiac disorders or lung
cancer, this subgroup was not analyzed separately.
Based on our findings, we conclude that ATP administra-
tion at home is safe. First, the majority of infusions (63%) are
without side effects, and second, our results confirm a
previous study in lung cancer patients [19] showing that side
578 Invest New Drugs (2007) 25:571–579effects that do appear are mild and transient, resolving within
minutes after lowering the ATP infusion rate. Nevertheless, it
remains possible that some side effects could be prevented
by encouraging patients to report any side effects without
delay. This emphasizes the need for careful instruction and
facilitating patients reporting and monitoring of side effects
when ATP infusions are administered at home. As patients
with cardiac disorders and lung cancer appear to have a
lower MTD and more side effects, these patients should be
monitored with special care.
Acknowledgements This study was supported as a part of the
programme “Palliative Care in the Terminal Phase” of The Netherlands
Organization for Health Research and Development (ZonMw), and by
the ‘Stichting Nationaal Fonds tegen Kanker’ (Foundation National
FundagainstCancer),TheNetherlands.Theauthorswouldliketothank
Nicole Wijckmans for assistance with measurements and logistics.
References
1. Agteresch HJ, Dagnelie PC, van Der Gaast A, Stijnen T, Wilson
JH (2000) Randomized clinical trial of adenosine 5′-triphosphate
in patients with advanced non-small-cell lung cancer. J Natl
Cancer Inst 92(4):321–328
2. Agteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson
JH, Dagnelie PC (2002) Beneficial effects of adenosine triphos-
phate on nutritional status in advanced lung cancer patients: a
randomized clinical trial. J Clin Oncol 20(2):371–378
3. Agteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie
PC (2003) Randomized clinical trial of adenosine 5′-triphosphate
on tumor growth and survival in advanced lung cancer patients.
Anticancer Drugs 14(8):639–644
4. Haskell CM, Wong M, Williams A, Lee LY (1996) Phase I trial of
extracellular adenosine 5′-triphosphate in patients with advanced
cancer. Med Pediatr Oncol 27(3):165–173
5. Haskell CM, Mendoza E, Pisters KM, Fossella FV, Figlin RA
(1998) Phase II study of intravenous adenosine 5′-triphosphate in
patients with previously untreated stage IIIB and stage IV non-
small cell lung cancer. Invest New Drugs 16(1):81–85
6. Domanovits H, Laske H, Stark G, Sterz F, Schmidinger H,
Schreiber W, Müllner M, Laggner AN (1994) Adenosine for the
management of patients with tachycardias—a new protocol. Eur
Heart J 15(5):589–593
7. Rankin AC, Oldroyd KG, Chong E, Dow JW, Rae AP, Cobbe SM
(1990) Adenosine or adenosine triphosphate for supraventricular
tachycardias? Comparative double-blind randomized study in
patients with spontaneous or inducible arrhythmias. Am Heart J
119(2 Pt 1):316–323
8. Fukuda K, Hayashida M, Fukunaga A, Kasahara M, Koukita Y,
Ichinohe T, Kaneko Y (2007) Pain-relieving effects of intravenous
ATP in chronic intractable orofacial pain: an open-label study.
J Anesth 21(1):24–30
9. Komukai K, Hashimoto K, Shibata T, Iwano K, Muto M, Mogi J,
Imai K, Horie T, Mochizuki S (2002) Effect of continuous ATP
injection on human hemodynamics. Circ J 66(10):926–929
10. Gaba SJ, Prefaut C (1990) Comparison of pulmonary and
systemic effects of adenosine triphosphate in chronic obstructive
pulmonary disease-ATP: a pulmonary controlled vasoregulator?
Eur Respir J 3(4):450–455
11. Holdgate A, Foo A (2006) Adenosine versus intravenous calcium
channel antagonists for the treatment of supraventricular tachy-
cardia in adults. Cochrane Database Syst Rev CD005154, (4)
12. Rankin AC, Oldroyd KG, Chong E, Rae AP, Cobbe SM (1989)
Value and limitations of adenosine in the diagnosis and treatment of
narrow and broad complex tachycardias. Br Heart J 62(3):195–203
13. DiMarco JP, Miles W, Akhtar M, Milstein S, Sharma AD, Platia
E, McGovern B, Scheinman MM, Govier WC (1990) Adenosine
for paroxysmal supraventricular tachycardia: dose ranging and
comparison with verapamil. Assessment in placebo-controlled,
multicenter trials. The Adenosine for PSVT Study Group
[published erratum appears in Ann Intern Med 1990 Dec 15;113
(12):996]. Ann Intern Med 113(2):104–110
14. Sethi KK, Singh B, Kalra GS, Arora R, Khalilullah M (1994)
Comparative clinical and electrophysiologic effects of adenosine
and verapamil on termination of paroxysmal supraventricular
tachycardia. Indian Heart J 46(3):141–144
15. Nesser HJ, Yao J, Soman P, Tkalec W, Ebner C, Steringer-
Mascherbauer R, Markt B, Samenuk D, Ng CK, Morcerf F,
Udelson JE, Pandian NG (2006) A head-to-head comparison of
infusion and bolus doses of adenosine for stress myocardial
contrast echocardiography. Echocardiography 23(6):483–489
16. Losek JD, Endom E, Dietrich A, Stewart G, Zempsky W, Smith K
(1999) Adenosine and pediatric supraventricular tachycardia in
the emergency department: multicenter study and review. Ann
Emerg Med 33(2):185–191
17. Seet CM (1997) Efficacy of intravenous adenosine in treatment of
paroxysmal supraventricular tachycardia in the local population.
Singapore Med J 38(12):525–528
18. Verani MS, Mahmarian JJ, Hixson JB, Boyce TM, Staudacher RA
(1990) Diagnosis of coronary artery disease by controlled coronary
vasodilation with adenosine and thallium-201 scintigraphy in patients
unable to exercise [see comments]. Circulation 82(1):80–87
19. Agteresch HJ, Dagnelie PC, Rietveld T, van den Berg JW, Danser
AH, Wilson JH (2000) Pharmacokinetics of intravenous ATP in
cancer patients. Eur J Clin Pharmacol 56(1):49–55
20. Beijer S, van Rossum E, Hupperets PS, Spreeuwenberg C, van
den Beuken M, Winkens RA, Ars L, van den Borne BE, de Graeff
A, Dagnelie PC (2007) Application of adenosine 5′-triphosphate
(ATP) infusions in palliative home care: design of a randomized
clinical trial. BMC Public Health 7:4
21. National Cancer Institute (1999) Common Toxicity Criteria, version
2.0. Publish National Cancer Institute, Bethesda, MD (April 30)
22. Moser GH, Schrader J, Deussen A (1989) Turnover of adenosine
in plasma of human and dog blood. Am J Physiol 256(4 Pt 1):
C799–C806
Invest New Drugs (2007) 25:571–579 579